The challenge of recruiting suitable patients into clinical trials has always been a significant obstacle to drug and medical device development programs. The difficulty of generating evidence delays the introduction of new medical interventions and entails high costs. In a new Covid-19 context, the pharmaceutical industry is facing unprecedented pressure.